Flatiron Health Announces Research to Be Presented at ISPOR 2025
Article content
Flatiron's research at this year's conference highlights the ability of scalable, high-quality real-world oncology data and novel rigorous approaches for health outcomes research to support both research and regulatory use cases.
Article content
NEW YORK — Flatiron Health today announced its presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron's real-world data is featured across 15+ pieces of research to be presented at the conference, including eight Flatiron authored research posters. Additionally, Flatiron will participate in a panel discussion on the role of real-world evidence in precision medicine, including how real-world data can be leveraged across international borders to inform regulatory and reimbursement decisions within diverse healthcare systems.
Article content
'At this year's ISPOR, Flatiron scientists are using high-quality real-world data to validate novel methodologies that will shape the future of evidence generation and health outcomes research in oncology,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Leveraging innovative AI and machine learning, Flatiron is expanding the utility of global real-world evidence in regulatory decision-making and across a growing range of oncology use cases at an unprecedented scale.'
Article content
Highlights include:
Article content
a poster presentation validating the use of ML to extract real-world response from unstructured data in the electronic health records (EHR), offering a scalable and efficient method for generating high-quality oncology real-world data
a poster presentation highlighting the acceptance of real-world evidence by the US Food and Drug Administration and the European Medicines Agency, underscoring its potential to complement traditional clinical trial data
a poster presentation introducing the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within EHR systems in Japan
Article content
Schedule a meeting with Flatiron Health at ISPOR 2025, and learn more about our abstracts and events, including workshops and panels.
Article content
Follow Flatiron Health on X and LinkedIn for more updates from #ISPORAnnual and visit us in person at Booth #601.
Article content
Using Regression Discontinuity in Time Design for Real-World Comparative Effectiveness: A Case Study for the Second-Line Use of Pembrolizumab in Advanced Non-Small Cell Lung Cancer Author Affiliations: Flatiron Health, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health
Nai-Chia Chen, Antal Zemplenyi, Blythe Adamson, Alex M. Kaizer, Cindy O'Bryant, R. Brett McQueen, Kelly E. Anderson
Poster Session 3
Poster Code: MSR87
Article content
Performance Assessment and Validation of Real-World Response Data Generated Using a Deep Learning-Based Natural Language Processing Model Across Multiple Solid Tumors Kelly Magee, Qianyu Yuan, Auriane Blarre, Aaron Cohen, Aaron Dolor, Konstantin Krismer, Tori Williams, Cherie Zhang
Poster Session 5
Poster Code: MSR142
Article content
From Data to Decisions: The Role of Real-World Evidence in Recent Multiple Myeloma Drug Approvals in the US and EU Mamta Parikh, Peter McMahon, Susan Eng, Freda Boateng, Youssef Ghazi, Kerstin Schmidt, Michelle Brockman, Mitch Sierecki
Poster Session 5
Poster Code: HPR136
Article content
Advancing Breast Cancer Research in Japan Using EHR-Derived Real-World Data Blythe Adamson, Dionne Ng, Harlan Pittel, Arun Sujenthiran, Eri Tajima
Poster Session 5
Poster Code: RWD143
Article content
Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer Author Affiliations: Flatiron Health, Tennessee Oncology, Jazz Pharmaceuticals
Wade Iams, Taavy Miller, Samantha Reiss, Navit Naveh, Badri Rengarajan, Amy Nguyen, Kristin J. Moore, Xiaozhou Fan
Poster Session 5
Poster Code: HSD69
Article content
Augmenting Race and Ethnicity in a Real-World Oncology Cohort Using the Bayesian Improved Surname Geocoding Methodology Gene Ho, Philani Mpofu, Olive Mbah, Cleo Ryals
Poster Session 5
Poster Code: MSR136
Article content
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
27-05-2025
- Cision Canada
Markel launches solutions for Financial Institutions in Australia
MELBOURNE, Australia, May 27, 2025 /CNW/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE: MKL), today announced it has launched Financial Institutions (FI) solutions in Australia, with localised wordings to service a broad range of organisations in the sector. This announcement follows the launch of localised Commercial Professional Indemnity solutions in 2024, under Markel's plan to progressively launch targeted and tailored specialty insurance products in the Australian market. Markel now has a primary Investment Managers Insurance policy available to Australian customers, with three additional primary wordings to be released in July 2025: Financial Institutions – Directors and Officers Financial Institutions – Professional Indemnity Financial Institutions – Crime These solutions are designed for private and listed local FIs, including private equity funds, mutual funds, venture capital funds, non-bank commercial and consumer lenders, credit unions, real estate investment trusts (REITs), superannuation funds, banks, investment companies, FinTech companies, and more. Leading the new FI solutions team will be Senior Underwriter in Professional and Financial Risks, Lan Pham, based in Melbourne, and Senior Underwriter Daisy Galvin, who has transferred to Sydney from Markel's London office. With specialist underwriters and dedicated claims handlers now onshore, Markel can provide local underwriting expertise, breadth of cover and professional claims service in Australia. Kym Beazleigh, Head of Professional and Financial Risks Australia at Markel, said, "We have seen growing demand across Australia for financial lines, particularly for financial institutions. This has been driven in part by the growth of the digital economy alongside traditional industries, increased scrutiny on director liability, and a spate of high-profile cyber breaches. "By nature, financial organisations face many threats in a highly regulated and complex industry. Financial institutions must protect their assets from risks such as climate and ESG disclosure, cybersecurity threats, and regulatory or legislative changes. If they're inadequately managed, they can cause significant damage to an institution and their clients' financial portfolios. We understand these risks and provide dynamic insurance solutions to fulfil the unique needs of the financial sector." Rory Morison, Managing Director of Australia at Markel, said, "The launch of these localised FI solutions follows last year's focus on Commercial Professional Indemnity and marks the next part of our journey since entering the Australian market in 2023. "We see a genuine need for more locally empowered underwriters in Australia, and we're excited to have Daisy join us from our London office to bolster our expertise in the FI space. We're very excited to bring these products to market, which combine the best of what Markel offers globally with our local IP and expertise." About Markel Insurance We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
CTV News
14-05-2025
- CTV News
‘It's illegal': Safety concerns in the skilled trades
A skilled technician in a bright orange safety jacket and hard hat prepares electrical wiring with precision. Tools and open cases are spread in the background, showcasing a professional workspace. (Source: Getty Images) (ultramansk/Getty Images)
National Post
14-05-2025
- National Post
Komodo Health's Real-World Evidence Platform Drives 31 Patient Journey Research Studies at ISPOR 2025
Article content Comprehensive Patient Journey Data Links Clinical Outcomes to Real-World Impact, Addressing Critical Evidence Gaps in Oncology, Neurology, Cardiovascular, Metabolic, and Rare Diseases Article content Article content MONTREAL — Komodo Health today announced that its healthcare intelligence platform enabled 31 research studies being presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. These include three studies led by Komodo researchers and 27 collaborative studies with academic institutions, Life Sciences companies, and healthcare organizations. Article content 'The volume and diversity of research powered by our healthcare insights underscore the growing demand for high-quality real-world data combined with advanced analytical capabilities,' said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. 'By connecting individual patient journeys to large-scale health outcomes, we're enabling researchers to uncover actionable insights that improve clinical practice, healthcare policy, and patient outcomes.' Article content The ISPOR 2025 research presentations demonstrate the value of Komodo's real-world evidence across a wide range of therapeutic areas, including: Article content Oncology: Salix Pharmaceuticals, Analysis Group, and Bausch Health studied the economic burden of opioid-induced constipation among patients with or without cancer; Cardiovascular disease: Veradigm examined the discordance between apolipoprotein B and low-density lipoprotein cholesterol levels in predicting incident hypertension risk and how it correlates to differential hypertension development patterns between diabetic and non-diabetic populations; Metabolic disorders: Novo Nordisk studied non-invasive diagnostic approaches and earlier interventions for metabolic dysfunction-associated steatohepatitis (MASH); Neurology: Jazz Pharmaceuticals analyzed healthcare resource utilization and costs among individuals with narcolepsy or idiopathic hypersomnia (IH) who are considered at higher risk for negative clinical outcomes associated with sodium (due to underlying cardiovascular, cardiometabolic, or renal conditions); and Rare disease: Chiesi analyzed medical claims data to better understand healthcare resource utilization patterns among Fabry disease patients Article content Three poster presentations by Komodo researchers also showcase methodological advances: Article content Komodo provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, including lab results, genomics, and demographic information — through its platform to address fundamental challenges in health economics and outcomes research (HEOR). Whereas HEOR teams have traditionally relied on fragmented, incomplete datasets that provide only narrow snapshots of patients' in-network healthcare experiences, Komodo's platform enables researchers to link disparate datasets without the months typically spent on data cleaning and integration. The option to enhance disease understanding at the patient level with lab, EHR, patient insurance, race and ethnicity, and mortality data enables teams to self-serve cohort feasibility and insights. This ability accelerates study planning timelines by weeks and generates more accurate estimates of treatment patterns, healthcare resource utilization, and costs. Article content 'By closing critical data gaps and providing a patient-centric approach to HEOR, our powerful, all-in-one platform brings clean, connected, and compliant real-world data together,' Nathoo added. 'We eliminate the need for messy integrations, manual data wrangling, and coding cohorts from scratch, which enables HEOR teams to generate evidence faster. The inclusion of race, ethnicity, mortality, and other demographic insights at a near-census level also allows researchers to better model the clinical and financial impacts of new therapies across diverse populations, addressing the reality that disease burden is not borne equally across demographic groups.' Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Rowena Kelley 858.255.1651 media@ Article content Article content Article content
